[1] |
Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study[J]. Lancet Neurol, 2014, 13(6):575-586.
doi: 10.1016/S1474-4422(14)70051-1
pmid: 24703753
|
[2] |
Grüter T, Möllers F E, Tietz A, et al. Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease[J]. Brain, 2023, 146(2):600-611.
doi: 10.1093/brain/awac090
URL
|
[3] |
Vanaveski T, Singh K, Narvik J, et al. Promoter-Specific Expression and Genomic Structure of IgLON Family Genes in Mouse[J]. Front Neurosci, 2017, 11:38.
|
[4] |
Zhang Y H, Ni Y, Gao Y N, et al. Anti-IgLON5 disease: a novel topic beyond neuroimmunology[J]. Neural Regen Res, 2023, 18(5):1017-1022.
doi: 10.4103/1673-5374.355742
URL
|
[5] |
Lim J H, Beg M M A, Ahmad K, et al. IgLON5 Regulates the Adhesion and Differentiation of Myoblasts[J]. Cells, 2021, 10(2):417.
doi: 10.3390/cells10020417
URL
|
[6] |
Karis K, Eskla K L, Kaare M, et al. Altered Expression Profile of IgLON Family of Neural Cell Adhesion Molecules in the Dorsolateral Prefrontal Cortex of Schizophrenic Patients[J]. Front Mol Neurosci, 2018, 11:8.
doi: 10.3389/fnmol.2018.00008
pmid: 29434535
|
[7] |
Chen W, Huang J, Xiong J, et al. Identification of a Tumor Microenvironment-Related Gene Signature Indicative of Disease Prognosis and Treatment Response in Colon Cancer[J]. Oxid Med Cell Longev, 2021, 2021:6290261.
|
[8] |
Xiong W, Feng S, Wang H, et al. Identification of candidate genes and pathways in limonin-mediated cardiac repair after myocardial infarction[J]. Biomed Pharmacother, 2021, 142:112088.
doi: 10.1016/j.biopha.2021.112088
pmid: 34470729
|
[9] |
Gaig C, Ercilla G, Daura X, et al. HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease[J]. Neurol Neuroimmunol Neuroinflamm, 2019, 6(6):e605.
doi: 10.1212/NXI.0000000000000605
URL
|
[10] |
Strippel C, Heidbreder A, Schulte-Mecklenbeck A, et al. Increased Intrathecal B and Plasma Cells in Patients With Anti-IgLON5 Disease: A Case Series[J]. Neurol Neuroimmunol Neuroinflamm, 2022, 9(2):e1137.
|
[11] |
Sabater L, Planagumà J, Dalmau J, et al. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome[J]. J Neuroinflammation, 2016, 13(1):226.
doi: 10.1186/s12974-016-0689-1
URL
|
[12] |
Landa J, Gaig C, Plagumà J, et al. Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration[J]. Ann Neurol, 2020, 88(5):1023-1027.
doi: 10.1002/ana.v88.5
URL
|
[13] |
Ryding M, Gamre M, Nissen M S, et al. Neurodegeneration Induced by Anti-IgLON5 Antibodies Studied in Induced Pluripotent Stem Cell-Derived Human Neurons[J]. Cells, 2021, 10(4):837.
doi: 10.3390/cells10040837
URL
|
[14] |
Alvente S, Matteoli G, Molina-Porcel L, et al. Pilot Study of the Effects of Chronic Intracerebroventricular Infusion of Human Anti-IgLON5 Disease Antibodies in Mice[J]. Cells, 2022, 11(6):1024.
doi: 10.3390/cells11061024
URL
|
[15] |
Ni Y, Feng Y, Shen D, et al. Anti-IgLON5 antibodies cause progressive behavioral and neuropathological changes in mice[J]. J Neuroinflammation, 2022, 19(1):140.
doi: 10.1186/s12974-022-02520-z
|
[16] |
Ye F, Fan C, Peng M, et al. Anti-IgLON5 disease in a pediatric patient with Langerhans cell histiocytosis[J]. Clin Chim Acta, 2021, 521:212-214.
doi: 10.1016/j.cca.2021.07.008
pmid: 34270954
|
[17] |
Gelpi E, Höftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy[J]. Acta Neuropathol, 2016, 132(4):531-543.
doi: 10.1007/s00401-016-1591-8
pmid: 27358064
|
[18] |
Schöberl F, Levin J, Remi J, et al. IgLON5: A case with predominant cerebellar tau deposits and leptomeningeal inflammation[J]. Neurology, 2018, 91(4):180-182.
doi: 10.1212/WNL.0000000000005859
pmid: 29970401
|
[19] |
Erro M E, Sabater L, Martínez L, et al. Anti-IGLON5 disease: A new case without neuropathologic evidence of brainstem tauopathy[J]. Neurol Neuroimmunol Neuroinflamm, 2019, 7(2):e651.
doi: 10.1212/NXI.0000000000000651
URL
|
[20] |
Montagna M, Amir R, De Volder I, et al. IgLON5-Associated Encephalitis With Atypical Brain Magnetic Resonance Imaging and Cerebrospinal Fluid Changes[J]. Front Neurol, 2018, 9:329.
doi: 10.3389/fneur.2018.00329
pmid: 29867738
|
[21] |
Cabezudo-García P, Mena-Vázquez N, Estivill Torrús G, et al. Response to immunotherapy in anti-IgLON5 disease: A systematic review[J]. Acta Neurol Scand, 2020, 141(4):263-270.
doi: 10.1111/ane.13207
pmid: 31853949
|
[22] |
Hughes E G, Peng X, Gleichman A J, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis[J]. J Neurosci, 2010, 30(17):5866-5875.
doi: 10.1523/JNEUROSCI.0167-10.2010
pmid: 20427647
|
[23] |
Scheggia D, Stanic J, Italia M, et al. GluA3 autoantibo-dies induce alterations in dendritic spine and behavior in mice[J]. Brain Behav Immun, 2021, 97:89-101.
doi: 10.1016/j.bbi.2021.07.001
pmid: 34246733
|
[24] |
Alberti P, Semperboni S, Cavaletti G, et al. Neurons: The Interplay between Cytoskeleton, Ion Channels/Transporters and Mitochondria[J]. Cells, 2022, 11(16):2499.
doi: 10.3390/cells11162499
URL
|
[25] |
Dendrou C A, Fugger L, Friese M A. Immunopathology of multiple sclerosis[J]. Nat Rev Immunol, 2015, 15(9):545-558.
doi: 10.1038/nri3871
pmid: 26250739
|
[26] |
Howell O W, Reeves C A, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis[J]. Brain, 2011, 134(Pt 9):2755-2771.
doi: 10.1093/brain/awr182
pmid: 21840891
|
[27] |
Correale J, Gaitán M I, Ysrraelit M C, et al. Progressive multiple sclerosis: from pathogenic mechanisms to treatment[J]. Brain, 2017, 140(3):527-546.
doi: 10.1093/brain/aww258
pmid: 27794524
|
[28] |
Meier-Stephenson F S, Meier-Stephenson V C, Carter M D, et al. Alzheimer′s disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites[J]. Alzheimers Dement (N Y), 2022, 8(1):e12283.
|
[29] |
Tan E K, Chao Y X, West A, et al. Parkinson disease and the immune system-associations, mechanisms and therapeutics[J]. Nat Rev Neurol, 2020, 16(6):303-318.
doi: 10.1038/s41582-020-0344-4
|